Design and rationale for a randomized, controlled trial of interpersonal psychotherapy and citalopram for depression in coronary artery disease (CREATE)

Psychosomatic Medicine

Volumn 68, Issue 1, 2006, Pages 87-93

  Frasure Smith, Nancy ^a,b,f,g   Koszycki, Diana ^c,h   Swenson, John Robert ^c,h,i   Baker, Brian ^d   Van Zyl, Louis T ^e   Laliberté, Marc André ^b,f   Abramson, Beth L ^j   Lambert, Jean ^b   Gravel, Ginette ^f   Lespérance, François ^a,b,f,g  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

^f MONTREAL HEART INSTITUTE   (Canada)

^g CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^h ROYAL OTTAWA HOSPITAL   (Canada)

ⁱ UNIVERSITY OF OTTAWA HEART INSTITUTE   (Canada)

^j ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

2 by 2 factorial; Clinical trial; Coronary artery disease; Psychotherapy; Selective serotonin reuptake inhibitor; Telephone assessment

Indexed keywords

CITALOPRAM; PLACEBO;

ARTICLE; BECK DEPRESSION INVENTORY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEPRESSION; EVIDENCE BASED MEDICINE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIAL; SELF REPORT; STRUCTURED CLINICAL INTERVIEW FOR DEPRESSION; STRUCTURED INTERVIEW;

CITALOPRAM; CORONARY ARTERIOSCLEROSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; PSYCHOTHERAPY; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 33646484844     PISSN: 00333174     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.psy.0000195833.68482.27     Document Type: Article

References (50)

1. Rumsfeld JS, Ho PM. Depression and cardiovascular disease: a call for recognition. Circulation 2005;111:250-3.
2. CANMAT Depression Work Group. Clinical guidelines for the treatment of depressive disorders. Can J Psychiatry 2001.
3. Jarrett RB, Rush AJ. Short-term psychotherapy of depressive disorders: current status and future directions. Psychiatry 1994;57:115-32.
4. Schulberg HC, Katon W, Simon GE, Rush AJ. Treating major depression in primary care practice: an update of the agency for health care policy and research practice guidelines. Arch Gen Psychiatry 1998;55:1121-7.
5. Fawcett J, Barkin RL. Efficacy issues with antidepressants. J Clin Psychiatry 1997;58(suppl 6):32-9.
6. Cohen-Cole SA, Kaufman KG. Major depression in physical illness: diagnosis, prevalence, and antidepressant treatment (a ten year review: 1982-1992). Depression 1993;1:181-204.
7. Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients: risk-benefit reconsidered. JAMA 1993;269:2673-5.
8. Glassman AH, O'Connor CM, Califf R, Swedberg K, Schwartz P, Bigger JT Jr, Krishnan KRR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Harrison WM, for the SADHART Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-9.
9. ENRICHD Investigators. Effects of treating depression and low perceived social support on clinical events after myocardial infarction. JAMA 2003;289:3106.
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
11. Klerman GL, Weissman MM, Rounsaville BJ, Chevron ES. Interpersonal Psychotherapy of Depression. Northvale, NJ: Jason Aronsin Inc; 1984.
12. Weissman MM, Prusoff BA, Dimascio A, Neu C, Goklaney M, Klerman GL. The efficacy of drugs and psychotherapy in the treatment of acute depressive episodes. Am J Psychiatry 1979;136:555-8.
13. Elkin I, Shea MT, Watkins JT, Imber SD, Sotsky SM, Collins JF, Glass DR, Pilkonis PA, Leber WR, Docherty JP, Fiester SJ, Parloff MB. National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 1989;46:971-82.
14. Reynolds CF III, Frank E, Perel JM, Imber SD, Cornes C, Miller MD, Mazumdar S, Houck PR, Dew MA, Stack JA, Pollock BG, Kupfer DJ. Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older then 59 years. JAMA 1999;281:39-45.
15. The ENRICHD Investigators. Enhancing recovery in coronary heart disease (ENRICHD) study intervention: rationale and design. Psychosom Med 2001;63:747-55.
16. Markowitz JC, Kocsis JH, Fishman B, Spielman LA, Jacobsberg LB, Frances AJ, Klerman GL, Perry SW. Treatment of depressive symptoms in human immunodeficiency virus-positive patients. Arch Gen Psychiatry 1998;55:452-7.
17. Frasure-Smith N, Lespérance F, Gravel G, Masson A, Juneau M, Talajic M, Bourassa MG. Social support, depression and mortality during the first year after myocardial infarction. Circulation 2000;101:1919-24.
18. Montgomery SA, Djarv L. The antidepressant efficacy of citalopram. Int Clin Psychopharmacol 1996;11(suppl 1):29-33.
19. Greenblatt DJ, von Moltke LL, Shader RI. Drug interactions with newer antidepressants: the role of human cytochromes P450. J Clin Psychiatry 1998;59(suppl 15):19-27.
20. Tan JY, Levin GM. Citalopram in the treatment of depression and other potential uses in psychiatry. Pharmacotherapy 1999;19:675-89.
21. Rasmussen SL, Overo KF, Tanghoj P. Cardiac safety of citalopram: prospective trials and retrospective analyses. J Clin Psychopharmacol 1999;19:407-15.
22. Klein DF. Control groups in pharmacotherapy and psychotherapy evaluations. Treatment 1997;1:10.
23. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management-imipramine/placebo administration manual: NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull 1987;23:309-24.
24. Miller MD, Pollock BP, Reynolds CF III. Medication clinic training procedures and treatment manual. 1998;1-21.
25. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured Clinical Interview for DSM-IV Axis I Disorders. New York, NY: Biometrics Research Department, New York State Psychiatric Institute; 1996.
26. Campeau L. The Canadian Cardiovascular Society grading of angina pectoris revisited 30 years later. Can J Cardiol 2002;18:371-9.
27. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
28. Hyman SE, Shore D. An NIMH perspective on the use of placebos. Biol Psychiatry 2000;47:689-91.
29. Kirsch I, Sapirstein G. Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Prevention and Treatment 1998;1(article 0002a):17 pages.
30. Fava M, Rush AJ, Trivedi MH, Nierenberg AA, Thase ME, Sackeim HA, Quitkin FM, Wisniewski S, Lavori PW, Rosenbaum JF, Kupfer DJ. Background and rationale for the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. Psychiatr Clin North Am 2003;26:457-494.
31. Rush AJ, Giles DE, Schlesser MA, Fulton CL, Weissenburger J, Burns C. The inventory for depressive symptomatology (IDS): preliminary findings. Psychiatry Res 1986;18:65-87.
32. Beck AT, Steer RA, Brown GK. Beck Depression Inventory Manual. 2nd ed. San Antonio: The Psychological Corporation, Harcourt Brace & Company; 1996.
33. Tilden VP, Nelson CA, May BA. The IPR Inventory: development and psychometric characteristics. Nurs Res 1990;39:337-43.
34. Donald CA, Ware JE Jr. The measurement of social support. Res Commun Mental Health 1984;4:325-70.
35. Leidy NK. Psychometric properties of the functional performance inventory in patients with chronic obstructive pulmonary disease. Nurs Res 1999;48:20-8.
36. Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
37. Gaston L. Reliability and criterion-related validity of the California Psychotherapy Alliance Scales-Patient Version: psychological assessment: a journal of consulting and clinical psychology 1991;3:68-74.
38. Weissman MM, Markowitz JC, Klerman GL. Comprehensive Guide to Interpersonal Psychotherapy. New York, NY: Basic Books; 2000.
39. Koszycki D, Lafontaine S, Frasure-Smith N, Swenson R, Lesperance F. An open-label trial of interpersonal psychotherapy in depressed patients with coronary disease. Psychosomatics 2004;45:319-24.
40. Serebruany VL, Glassman AH, Malinin AI, Sane DC, Finkel MS, Krishnan RR, Atar D, Lekht V, O'Connor CM. Enhanced platelet-endothelial activation in depressed patients with acute coronary syndromes: evidence from recent clinical trials. Blood Coagul Fibrinolysis 2003;14:563-7.
41. Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associates; 1988.
42. Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ, Markowitz JC, Nemeroff CB, Russell JM, Thase ME, Trivedi MH, Zajecka J. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000;342:1462-70.
43. Donner A. Approaches to sample size estimation in design of clinical trials: a review. Stat Med 1984;3:199-214.
44. Davis CE. Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance. Control Clin Trials 1997;18:557-60.
45. Shapiro PA, Lespérance F, Frasure-Smith N, O'Connor CM, Baker B, Jiang JW, Dorian P, Harrison W, Glassman AH. An open-label preliminary trial of sertraline for treatment of major depression after acute myocardial infarction (the SADHAT Trial). Am Heart J 1999;137:1100-6.
46. Lespérance F, Frasure-Smith N, Laliberté M-A, White M, Lafontaine S, Calderone A, Talajic M, Rouleau J-L. An open-label study of nefazodone treatment of major depression in patients with congestive heart failure. Can J Psychiatry 2003;48:695-701.
47. National Institute for Clinical Excellence. Depression: Management of Depression in Primary and Secondary Care: Clinical Practice Guideline No. 23. London: NICE; 2004. www.nice.org.uk/pdf/cg023fullguideline.pdf.
48. Pocock SJ. Clinical trials with multiple outcomes: a statistical perspective on their design, analysis, and interpretation. Control Clin Trials 1997;18:530-45.
49. Borenstein M, Rothstein H, Cohen J. SamplePower, Release 1.20. SPSS Inc.; 1997.
50. Schneiderman N, Saab PG, Catellier DJ, Powell LH, DeBusk RF, Williams RB, Carney RM, Raczynski JM, Cowan MJ, Berkman LF, Kaufmann PG. Psychosocial treatment within sex by ethnicity subgroups in the Enhancing Recovery in Coronary Heart Disease clinical trial. Psychosom Med 2004;66:475-83.